Avenue Therapeutics Statistics Share Statistics Avenue Therapeutics has 3.18M
shares outstanding. The number of shares has increased by 122.42%
in one year.
Shares Outstanding 3.18M Shares Change (YoY) 122.42% Shares Change (QoQ) 55% Owned by Institutions (%) 1.12% Shares Floating 2.83M Failed to Deliver (FTD) Shares 112 FTD / Avg. Volume 1.61%
Short Selling Information The latest short interest is 49.36K, so 1.55% of the outstanding
shares have been sold short.
Short Interest 49.36K Short % of Shares Out 1.55% Short % of Float 1.55% Short Ratio (days to cover) 2.47
Valuation Ratios The PE ratio is -2.22 and the forward
PE ratio is -0.28.
Avenue Therapeutics's PEG ratio is
0.02.
PE Ratio -2.22 Forward PE -0.28 PS Ratio 0 Forward PS n/a PB Ratio 9.26 P/FCF Ratio -2.87 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Avenue Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.27,
with a Debt / Equity ratio of 0.
Current Ratio 3.27 Quick Ratio 3.27 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-5.83M Employee Count 2 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -83.4% in the
last 52 weeks. The beta is -0.01, so Avenue Therapeutics's
price volatility has been lower than the market average.
Beta -0.01 52-Week Price Change -83.4% 50-Day Moving Average 0.33 200-Day Moving Average 1 Relative Strength Index (RSI) 61.32 Average Volume (20 Days) 6,978
Income Statement
Revenue n/a Gross Profit n/a Operating Income -11.28M Net Income -11.65M EBITDA -11.28M EBIT n/a Earnings Per Share (EPS) -0.9
Full Income Statement Balance Sheet The company has 2.59M in cash and 0 in
debt, giving a net cash position of 2.59M.
Cash & Cash Equivalents 2.59M Total Debt n/a Net Cash n/a Retained Earnings -102.58M Total Assets 3.59M Working Capital 2.24M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -9.03M
and capital expenditures 0, giving a free cash flow of -9.03M.
Operating Cash Flow -9.03M Capital Expenditures n/a Free Cash Flow -9.03M FCF Per Share -0.7
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ATXI does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ATXI.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 26, 2024. It was a
backward
split with a ratio of 1:75.
Last Split Date Apr 26, 2024 Split Type backward Split Ratio 1:75
Scores Altman Z-Score -44.08 Piotroski F-Score 2
